Axinn Successfully Argues for Claim Construction in Mayne v. Merck
December 27, 2016
A team of Axinn attorneys successfully argued on behalf of Mayne Pharma International Pty Ltd. in a claim construction hearing in the patent infringement action, Mayne Pharma International Pty Ltd. v. Merck & Co., Inc. and Merck Sharp & Dohme Corp. On December 27, 2016, Judge Leonard P. Stark of the United States District Court for the District of Delaware issued a favorable opinion and order construing the claims to be limited to humans, as well as rejecting Merck’s contentions that the claims are invalid for indefiniteness.
The patent infringement matter alleges that Merck’s Noxafil® tablets infringe Mayne's U.S. Patent No. 6,881,745, which relates to pharmaceutical compositions for poorly soluble, antifungal drugs.
The team of Axinn attorneys consisted of Jason Murata, Thomas Hedemann, and Matt Murphy.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Earns Band 1 Recognition in Multiple Categories in 2025 Chambers USA Guide
News
Antitrust
Antitrust 101: Criminal Antitrust Enforcement in U.S. v. US Gypsum Co., 438 US 422 (1978)
Podcast
FTC Peeling Back the Layers of the Orange Book
Axinn Viewpoints
Intellectual Property
Patman Returns … and Retreats Again
Axinn Viewpoints
Antitrust
The Approach of Public and Private Enforcers to Data Use in the Financial Services Sector
Byline Articles
Antitrust
Axinn Successfully Reunites One of Its Pro Bono Clients, a Former Afghan Army Captain, with His Wife and Four Children
Pro Bono